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ﬁbrillation(NVAF) and further to provide the suggests for choosing reasonable ther-
apeutic schedule of these patients.
Methods: A total of 319 very elderly patients with nonvalvular atrial ﬁbrillation in
eight Department of Grade III hospitals was enrolled during May 2012 to
September 2013. The status of antithrombotic treatment was observed and a
follow-up of three to six months was given. The patients were divided into warfarin
group, antiplatelet group (aspirin or clopidogrel), dual antiplatelet group, warfarin
combined with antiplatelet group, new oral anticoagulants group (dabigatran) and
no antithrombotic group. Inﬂuential factors of antithrombotic treatment, main
terminal events (including bleeding, ischemic events and death) and its affecting
factors were analyzed.
Results: There were 192 men (60.20%) and 127 women (39.80%) involved in the
study and the average age was (84.663.54) years old. 41 patients used warfarin
anticoagulant therapy alone, 158 patients used antiplatelet therapy (aspirin or clo-
pidogrel) alone, 24 used dual antiplatelet, 7 patients used warfarin combined with
aspirin therapy, 7 patients used new oral anticoagulants therapy and 82 patients
were without any of antithrombotic therapies. According to CHADS2 index, there
were 314 patients suggested to use warfarin and the real percentage of using
warfarin was 15.29 %( 48/314). Of the total patients receiving warfarin, the ratio of
monitoring the international normalized ratio (INR) was 79.17 %( 38/48). The
average level of INR was (1.850.53).And patients’ INR between 1.6-2.5 were only
22 cases (57.89%). During the follow-up visits, 319 very elderly patients were
observed. The main terminal events were 90 cases (28.21%), while the bleeding,
ischemic events and death are 26(8.15%), 23 (7.21%) and 41 (12.85%) respectively.
The bleeding and ischemic events of the antithrombotic group is 2 (3.64%) and 3
(5.45%).
Conclusions: Warfarin is underused in very elderly patients with NVAF who had
indications of anticoagulation. And the ratio of targeted INR is not enough. The main
cause of non-anticoagulation. Is worring about bleeding. The antithrombotic group has
lower rate of bleeding and ischemic events. Therefore, the assessment of the risk of
thromboembolism in very elderly patients and the management of anticoagulant
therapy should be strengthened.
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Objectives: Pitavastatin is the most reccardiovasculartly approved statin which is
regarded as “superstatins”. This clinical trial was designed to investigate the efﬁcacy
of pitavastatin in treating hypercholesterolemia combined with chronic heart failure.
Methods: Forty-nine patients with hypercholesterolemia combined with chronic heart
failure were divided into the two groups randomly by the blind random method. The
observation group (24 patients) received pitavastatin while the control group (25pa-
tients) received atorvastatin. Both of the two groups received basic therapy of chronic
heart failure including digoxin, Katlex and spironolactone. After a 8-week treatment,
the total cholesterol(TC), low density lipoprotein cholesterol(LDL-C), triglycer-
ides(TG), high density lipoprotein cholesterol(HDL-C) were compared between the
two group.
Results: After treatment the decrease degree of TC and LDL-C in the two groups had
statistical differences (P<0.05).However, TG and HDL-C had no statistical differ-
ences (P>0.05). The reaching standard rate of the LDL-C level and the occurrence
rates of adverse reaction in the two groups had no statistical differences (P>0.05).
Conclusions: Pitavastatin has signiﬁcant effect in treating hypercholesterolemia
combined with chronic heart failure, which can reduce the TC, LDL-C levels, with
low rate of occurrence of adverse reactions. The effect of pitavastatin on the
improvement of chronic heart failure needs more investigation.
GW25-e5131
Efﬁcacy and Safety of Varenicline for Smoking Cessation in Patients with CAD
undergoing PCI
Wei Yujie, Liu Huliang
Department of Cardiology, General Hospital of Chinese People’s Armed Police
Forces
Objectives: This study focued on the efﬁcacy of varenicline and the safety of the
combination of two drugs by investigating the patients who were given clopidogrel
and varenicline with CAD undergoing PCI.
Methods: Eligible smoking patients in hospital, with CAD undergoing PCI were
consecutively included. All patients received aspirin (100 mg/day) and clopidogrel
(loading dose 300mg, followed by 75 mg/day). On 3 day after received clopidogrel
75mg/day, patients will be randomized to receive either associated varenicline or
without varenicline for 14 days. Blood samples will be collected before rendered
clopidogrel, on day 1 before associated varenicline, and on 14 day after associated
varenicline. Clopidogrel effect will be tested by measuring platelet phosphorylated-
VASP expressed as a platelet reactivity index (PRI). All patients were followed 6
months and they were documented smoking ceased rates, concomitant medication and
adverse events.JACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/CResults: The statistic comparison of the baseline data at admission in two groups
showed no signiﬁcant differences. In the conventional therapy group, PRI was
80.085.60%, 55.2114.87% and 43.0113.59% respectively at the three time. In
varenicline group, PRI was 79.945.18%, 53.7414.47% and 42.1811.27%
respectively at the three time. There was no signiﬁcant difference between the two
groups. The comparison of smoking ceased rates of two groups after 6 months: The
smoking cessation rate was 64.91% in the varenicline group. The smoking cessation
rate was 34.48%. The smoking cessation rate of the varenicline group was higher than
the control group (P<0.010). The data of eGFR were similar in the 2 groups. The
adverse events in varenicline group were higher than in conventional therapy group.
However, there was no signiﬁcant difference between the 2 groups. The serious
adverse events were identical between the 2 groups.
Conclusions: The rate of smoking cessation of varenicline was signiﬁcantly improved
in patients with CAD in periprocedure of PCI. Clopidogrel can be safely administrated
with varenicline without the need for dose adjustment.Cardiac Rehabilitation
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Objectives: Elevated left ventricular ﬁlling pressure (LVFP) is an important cause of
exercise intolerance in patients with atrial ﬁbrillation (AF). Exercise stress echocar-
diography could assess LVFP during exercise. The objective of this study was to
investigate the relationship between exercise induced elevation of LVFP estimated by
the ratio of early diastolic mitral inﬂow velocity (E) to early diastolic mitral annular
velocity (e’) and exercise capacity.
Methods: This study included 86 consecutive patients (48 men and 38 women;
mean age 64.69.2 years) with non-valvular AF and normal left ventricular systolic
function (left ventricular ejection fraction 50%). All patients underwent a symp-
tom-limited cardiopulmonary exercise test (CPET). Doppler echocardiography was
performed both at rest and immediately after exercise. Five consecutive measure-
ments of E and e’ were taken and averaged. E/e’ ratio was calculated. Elevated
LVFP was deﬁned as E/e’>9, and patients with elevated LVFP at rest were
excluded.
Results: Patients were classiﬁed into two groups according to LVFP estimated by E/e’
ratio after exercise: 64 (74.4%) with normal LVFP and 22 (25.6%) with elevated
LVFP after exercise. As compared with the patients with normal LVFP, the ones with
elevated LVFP after exercise had signiﬁcantly lower VO2 peak (22.02.6
vs 26.33.7 mL/min/kg, P<0.001), lower anaerobic thresbold (20.12.8 vs
25.74.0mL/min/kg, P<0.001), and shorter exercise time duration (6.20.9
vs 7.11.4min, P<0.001). Multivariate analysis identiﬁed 3 signiﬁcant variables that
are predicative of VO2 peak: age (r¼-0.412, P<0.001), gender (26.54.1 and
23.62.9mL/min/kg for male and female separately, P<0.001) and E /e’ after exercise
(r¼-0.607, P<0.001).
Conclusions: Elevated LVFP estimated by E/e’ ratio after exerceise is independently
associated with reduced exercise capacity. Exercise stress echocardiography could be
a useful diagnostic test for early diastolic dysfunction in AF patients.
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Objectives: To analyze variables (VO2/kg peak, VE/VCO2 nadir and VE/VCO2
slope) in cardiopulmonary exercise testing (CPET) among Chinese patients with
coronary artery disease (CAD) and to aid in developing more effective rehabilitation
programs.
Methods: This study was carried out in a cross-sectional observational way, and it
enrolled totally 38 CAD patients (30 have been treated by PCI and/or CABG) in
Guangdong General Hospital Cardiac Research Institute from November 1st, 2013 to
January 30th, 2014. After consent and clear of contraindications, every patient un-
derwent a CPET*, and patients were encouraged to exercise with maximal efforts. Aardiac Rehabilitation C207
